KR102821649B1 - 디하이드로오로테이트 데하이드로게나제의 억제 방법 및 조성물 - Google Patents

디하이드로오로테이트 데하이드로게나제의 억제 방법 및 조성물 Download PDF

Info

Publication number
KR102821649B1
KR102821649B1 KR1020217002054A KR20217002054A KR102821649B1 KR 102821649 B1 KR102821649 B1 KR 102821649B1 KR 1020217002054 A KR1020217002054 A KR 1020217002054A KR 20217002054 A KR20217002054 A KR 20217002054A KR 102821649 B1 KR102821649 B1 KR 102821649B1
Authority
KR
South Korea
Prior art keywords
delete delete
compound
cancer
disclosed
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217002054A
Other languages
English (en)
Korean (ko)
Other versions
KR20210048483A (ko
Inventor
죤 씨 바이르드
토마스 이 굳윈
올라 엘가말
에린 헤르틀레인
모우아드 아브둘라힘
챠드 이 벤네트
샌딥 매드후카르 비브후트
Original Assignee
오하이오 스테이트 이노베이션 파운데이션
헨드릭스 칼리지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오하이오 스테이트 이노베이션 파운데이션, 헨드릭스 칼리지 filed Critical 오하이오 스테이트 이노베이션 파운데이션
Publication of KR20210048483A publication Critical patent/KR20210048483A/ko
Application granted granted Critical
Publication of KR102821649B1 publication Critical patent/KR102821649B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217002054A 2018-06-22 2019-06-22 디하이드로오로테이트 데하이드로게나제의 억제 방법 및 조성물 Active KR102821649B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688612P 2018-06-22 2018-06-22
US62/688,612 2018-06-22
PCT/US2019/038622 WO2019246603A1 (en) 2018-06-22 2019-06-22 Methods and compositions for inhibition of dihydroorotate dehydrogenase

Publications (2)

Publication Number Publication Date
KR20210048483A KR20210048483A (ko) 2021-05-03
KR102821649B1 true KR102821649B1 (ko) 2025-06-17

Family

ID=68984309

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217002054A Active KR102821649B1 (ko) 2018-06-22 2019-06-22 디하이드로오로테이트 데하이드로게나제의 억제 방법 및 조성물

Country Status (14)

Country Link
US (3) US11312686B2 (enExample)
EP (2) EP4438042A3 (enExample)
JP (1) JP7373170B2 (enExample)
KR (1) KR102821649B1 (enExample)
CN (1) CN112672744B (enExample)
AU (2) AU2019288813B2 (enExample)
BR (1) BR112020026308A2 (enExample)
CA (1) CA3103557A1 (enExample)
ES (1) ES2994093T3 (enExample)
IL (1) IL279586B (enExample)
MX (1) MX2021000143A (enExample)
SG (1) SG11202012029PA (enExample)
WO (1) WO2019246603A1 (enExample)
ZA (1) ZA202007620B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773579A4 (en) 2018-03-26 2022-03-09 Clear Creek Bio, Inc. COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
EP4081215B1 (en) * 2019-12-26 2026-05-20 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
WO2021134045A1 (en) * 2019-12-26 2021-07-01 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd38 therapeutic agent
JP2023518419A (ja) * 2020-03-20 2023-05-01 クリア クリーク バイオ， インコーポレイテッド ブレキナルナトリウムの安定した多形性組成物ならびにその使用および製造方法
US12076315B2 (en) 2020-03-20 2024-09-03 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
CN113943312A (zh) * 2020-07-17 2022-01-18 轶诺(浙江)药业有限公司 一类肠道裂解型共药及其制备和用途
WO2023278778A1 (en) * 2021-06-30 2023-01-05 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd47-sirpα therapeutic agent
CN115896025B (zh) * 2021-08-20 2025-08-26 合肥中科普瑞昇生物医药科技有限公司 人原代急性髓系白血病细胞的培养基及培养方法
EP4436579A4 (en) * 2021-11-22 2025-10-22 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR TARGETING ALTERNATIVE METABOLISM IN CONJUNCTION WITH FLT3 INHIBITOR-MEDIATED ANTILEUKEMIA ACTIONS
CN115532290B (zh) * 2022-10-13 2024-04-30 浙江昌海制药有限公司 一种特定晶面选择性氢化催化剂及其制备方法和应用
WO2025227007A1 (en) * 2024-04-26 2025-10-30 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042953A1 (en) * 1996-05-10 1997-11-20 Novartis Ag Use of brequinar and derivatives in chronic rejection of allografts and xenotransplantation
WO2001024785A2 (en) 1999-10-01 2001-04-12 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
WO2014117090A1 (en) * 2013-01-28 2014-07-31 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2018038886A1 (en) 2016-08-23 2018-03-01 Icahn School Of Medicine At Mount Sinai Methods for treating pten-mutant tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2888346A (en) * 1955-08-22 1959-05-26 Gen Aniline & Film Corp Ultra-violet absorbing compounds
US6841561B1 (en) 1999-10-01 2005-01-11 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
NZ535992A (en) 2002-05-17 2008-11-28 Aventis Pharma Sa Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
ES2694829T3 (es) 2013-02-25 2018-12-27 Aurigene Discovery Technologies Limited Derivados de benzotriazol trisustituido como inhibidores de dihidroorotato oxigenasa

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042953A1 (en) * 1996-05-10 1997-11-20 Novartis Ag Use of brequinar and derivatives in chronic rejection of allografts and xenotransplantation
WO2001024785A2 (en) 1999-10-01 2001-04-12 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
WO2014117090A1 (en) * 2013-01-28 2014-07-31 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2018038886A1 (en) 2016-08-23 2018-03-01 Icahn School Of Medicine At Mount Sinai Methods for treating pten-mutant tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry, (2018) Vol. 61, pp. 5162-5186*
Journal of Organic Chemistry, (1953) Vol. 18, pp. 1209-1224*

Also Published As

Publication number Publication date
US20220064119A1 (en) 2022-03-03
US11312686B2 (en) 2022-04-26
WO2019246603A1 (en) 2019-12-26
EP3793562C0 (en) 2024-06-19
KR20210048483A (ko) 2021-05-03
EP3793562B1 (en) 2024-06-19
EP4438042A2 (en) 2024-10-02
AU2019288813A1 (en) 2021-01-07
ZA202007620B (en) 2023-02-22
US20240294477A1 (en) 2024-09-05
CN112672744B (zh) 2022-10-14
EP3793562A1 (en) 2021-03-24
MX2021000143A (es) 2021-08-05
ES2994093T3 (en) 2025-01-17
EP3793562A4 (en) 2021-07-07
AU2023233065B2 (en) 2025-09-25
SG11202012029PA (en) 2021-01-28
JP7373170B2 (ja) 2023-11-02
AU2023233065A1 (en) 2023-10-05
CA3103557A1 (en) 2019-12-26
CN112672744A (zh) 2021-04-16
US20210253531A1 (en) 2021-08-19
EP4438042A3 (en) 2024-12-04
AU2019288813B2 (en) 2023-06-29
BR112020026308A2 (pt) 2021-03-30
IL279586A (en) 2021-01-31
US11999697B2 (en) 2024-06-04
JP2021530559A (ja) 2021-11-11
IL279586B (en) 2021-09-30

Similar Documents

Publication Publication Date Title
US20240294477A1 (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
JP2023508938A (ja) 抗ｃｄ３８治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物
WO2023172643A1 (en) The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancer
CN115361948B (zh) 抑制二氢乳清酸脱氢酶的方法和组合物
US20230089524A1 (en) Compositions for use in the inhibition of dihydroorotate dehydrogenase
US20230109418A1 (en) Compositions for use for the inhibition of dihydroorotate dehydrogenase
HK40043086A (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
JP2024525428A (ja) 抗ｃｄ４７－ｓｉｒｐα治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法及び組成物
HK40043086B (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
HK40084674A (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210121

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220622

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240626

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20250106

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250310

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250612

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250612

End annual number: 3

Start annual number: 1

PG1601 Publication of registration